Testing of New Drugs Approved From 2015 Through 2021 Under the US Pediatric Research Equity Act.
作者信息
Liu Ian T T, Hwang Thomas J, Kesselheim Aaron S
机构信息
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.
Now with Department of Pediatrics, University of Illinois at Chicago.
出版信息
JAMA. 2024 Nov 5;332(17):1482-1484. doi: 10.1001/jama.2024.18338.
Abstract
摘要
相似文献
1
Testing of New Drugs Approved From 2015 Through 2021 Under the US Pediatric Research Equity Act.2015年至2021年期间依据美国《儿科研究公平法案》获批新药的测试
JAMA. 2024 Nov 5;332(17):1482-1484. doi: 10.1001/jama.2024.18338.
2
Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.美国儿科研究公平法案下强制性儿科上市后研究的完成率和报告情况。
JAMA Pediatr. 2019 Jan 1;173(1):68-74. doi: 10.1001/jamapediatrics.2018.3416.
3
The RACE Act and Pediatric Trials of Adult Cancer Drugs.RACE 法案与成人癌症药物在儿科中的临床试验。
Pediatrics. 2024 Oct 1;154(4). doi: 10.1542/peds.2024-066920.
4
Mandatory requirements for pediatric drug development in the EU and the US for novel drugs-A comparative study.欧盟和美国对新型药物进行儿科药物开发的强制性要求——一项比较研究。
Front Med (Lausanne). 2022 Oct 31;9:1009432. doi: 10.3389/fmed.2022.1009432. eCollection 2022.
5
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs.儿童一岁时的RACE法案：分子靶向肿瘤药物儿科研发进展
Expert Rev Anticancer Ther. 2022 Mar;22(3):317-321. doi: 10.1080/14737140.2022.2032664. Epub 2022 Jan 24.
6
Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation.药物标签变更与儿科血液学/肿瘤学处方：衡量美国立法的影响。
Clin Trials. 2021 Dec;18(6):732-740. doi: 10.1177/17407745211030683. Epub 2021 Jul 16.
7
Pediatric Drug Policies Supporting Safe And Effective Use Of Therapeutics In Children: A Systematic Analysis.支持儿童安全有效使用治疗药物的儿科药物政策：系统分析
Health Aff (Millwood). 2020 Oct;39(10):1799-1805. doi: 10.1377/hlthaff.2020.00198.
8
Pediatric drug information available at the time of new drug approvals: A cross-sectional analysis.新药获批时可获取的儿科药物信息：一项横断面分析。
Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):161-167. doi: 10.1002/pds.4351. Epub 2017 Nov 17.
9
Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers.儿科癌症治疗的临床试验，目标可能与儿科癌症相关。
J Natl Cancer Inst. 2020 Mar 1;112(3):224-228. doi: 10.1093/jnci/djz207.
10
Clinical trial considerations for pediatric cancer drug development.儿科癌症药物研发的临床试验考量
J Biopharm Stat. 2023 Nov 2;33(6):859-874. doi: 10.1080/10543406.2023.2172424. Epub 2023 Feb 7.
引用本文的文献
1
US Government Spending on New Drugs With Incomplete and Postponed Mandatory Pediatric Trials.美国政府对未完成及推迟强制性儿科试验的新药的支出。
JAMA Pediatr. 2025 Sep 2. doi: 10.1001/jamapediatrics.2025.2817.
本文引用的文献
1
Clinical trials for paediatric cancers under new legislation in the USA.美国新立法下针对儿童癌症的临床试验。
Lancet Child Adolesc Health. 2023 Jul;7(7):e13. doi: 10.1016/S2352-4642(23)00125-6.
2
Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.美国儿科研究公平法案下强制性儿科上市后研究的完成率和报告情况。
JAMA Pediatr. 2019 Jan 1;173(1):68-74. doi: 10.1001/jamapediatrics.2018.3416.
3
Pediatric drug information available at the time of new drug approvals: A cross-sectional analysis.新药获批时可获取的儿科药物信息：一项横断面分析。
Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):161-167. doi: 10.1002/pds.4351. Epub 2017 Nov 17.
4
Orphan products: an emerging trend in drug approvals.孤儿药：药物审批中的一种新兴趋势。
Nat Rev Drug Discov. 2010 Jan;9(1):84. doi: 10.1038/nrd2546-c1.
Zotero 插件